Download PDF
Exp Clin Endocrinol Diabetes 2017; 125(05): 322-326
DOI: 10.1055/s-0043-104532
Article
© Georg Thieme Verlag KG Stuttgart · New York

Serum Fibroblast Growth Factor 1 is Associated with the Decreased Risk of Obesity in Human

Jinzhou Zhu   *
1   School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
,
Yuming Wang   *
2   Department of Geriatrics, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
,
Kefu Zhu
3   Department of Cardiology, Zhejiang Hospital, Hangzhou, Zhejiang, China
4   The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China
,
Jianguo Gao
1   School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
,
Xingyong Wan
1   School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
,
Xunlei Pang
5   Department of Gastroenterology, The Affiliated Hospital, Xuzhou Medical University, Xuzhou, Jiangsu, China
,
Sujuan Fei
5   Department of Gastroenterology, The Affiliated Hospital, Xuzhou Medical University, Xuzhou, Jiangsu, China
› Author Affiliations
Further Information

Publication History

received 13 September 2016
revised 19 February 2017

accepted 22 February 2017

Publication Date:
16 March 2017 (online)

Also available at
    Permissions and Reprints

Abstract

Background

As a transducer of PPARγ signaling, recent evidence supports that fibroblast growth factor 1 (FGF1) mediates adipose tissue remodeling and insulin sensitivity.

Aims

This study is to assess the role of serum FGF1 in obesity.

Methods

A hospital-based case-control study of 154 subjects was conducted. Serum level of FGF1 was measured by enzyme-linked immunosorbent assay.

Results

The serum level of FGF1 in the lean (119.0 [103.1–146.1] pg/ml) was higher than it in the subjects with overweight/obesity (111.9 [80.3–127.4] pg/ml, P=0.009). Binary logistic regression models found a reverse association between serum FGF1 level and the risk of overweight/obesity (adjusted odds ratio=0.990, 95% confidence interval [0.981–0.998], P=0.019). Furthermore, serum FGF1 reversely correlated with body mass index (r=−0.176, P=0.029), systolic blood pressure (r=−0.224, P=0.005), diastolic blood pressure (r=−0.185, P=0.022) and triglycerides (r=−0.162, P=0.044). Multiple stepwise linear regression analysis found serum level of FGF1 was dependent on anti-diabetic drugs, hemoglobin A1C, body mass index and sex.

Conclusions

Serum level of FGF1 is associated with the decreased risk of obesity in human.

Key words

case-control - fibroblast growth factor 1 (FGF1) - peroxisome proliferator-activated receptor γ (PPARγ) - obesity - diabetes

* J. Zhu and Y. Wang contributed equally to the work.


 

  • References

  • 1 Ogden CL, Carroll MD, Kit BK. et al. Prevalence of childhood and adult obesity in the United States, 2011–2012. Jama 2014; 311: 806-814 doi:10.1001/jama.2014.732
    CrossrefPubMedGoogle Scholar
  • 2 Jensen MD, Ryan DH, Apovian CM. et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation 2014; 129: S102-S138 doi:10.1161/01.cir.0000437739.71477.ee
    CrossrefPubMedGoogle Scholar
  • 3 Yumuk V, Tsigos C, Fried M. et al. European guidelines for obesity management in adults. Obesity facts 2015; 8: 402-424 doi:10.1159/000442721
    CrossrefPubMedGoogle Scholar
  • 4 Zhu JZ, Dai YN, Wang YM. et al. Prevalence of nonalcoholic fatty liver disease and economy. Digestive diseases and sciences 2015; 60: 3194-3202 doi:10.1007/s10620-015-3728-3
    CrossrefPubMedGoogle Scholar
  • 5 Hallenborg P, Petersen RK, Kouskoumvekaki I. et al. The elusive endogenous adipogenic PPARgamma agonists: Lining up the suspects. Progress in Lipid Research 2016; 61: 149-162 doi:10.1016/j.plipres.2015.11.002
    CrossrefPubMedGoogle Scholar
  • 6 Marciano DP, Chang MR, Corzo CA. et al. The therapeutic potential of nuclear receptor modulators for treatment of metabolic disorders: PPARgamma, RORs, and Rev-erbs. Cell metabolism 2014; 19: 193-208 doi:10.1016/j.cmet.2013.12.009
    CrossrefPubMedGoogle Scholar
  • 7 Soccio RE, Chen ER, Lazar MA. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell metabolism 2014; 20: 573-591 doi:10.1016/j.cmet.2014.08.005
    CrossrefPubMedGoogle Scholar
  • 8 Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nature Reviews Drug discovery 2009; 8: 235-253 doi:10.1038/nrd2792
    CrossrefPubMedGoogle Scholar
  • 9 Nies VJ, Sancar G, Liu W. et al. Fibroblast growth factor signaling in metabolic regulation. Frontiers in endocrinology 2015; 6: 193 doi:10.3389/fendo.2015.00193
    PubMedGoogle Scholar
  • 10 Jonker JW, Suh JM, Atkins AR. et al. A PPARgamma-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis. Nature 2012; 485: 391-394 doi:10.1038/nature10998
    CrossrefPubMedGoogle Scholar
  • 11 Fernandes-Freitas I, Owen BM. Metabolic roles of endocrine fibroblast growth factors. Current opinion in pharmacology 2015; 25: 30-35 doi:10.1016/j.coph.2015.09.014
    CrossrefPubMedGoogle Scholar
  • 12 Sun K, Scherer PE. The PPARgamma-FGF1 axis: An unexpected mediator of adipose tissue homeostasis. Cell research 2012; 22: 1416-1418 doi:10.1038/cr.2012.94
    CrossrefPubMedGoogle Scholar
  • 13 Kingwell K. Obesity and diabetes: FGF1 goes long to tackle diabetes. Nature reviews Drug discovery 2014; 13: 652-653 doi:10.1038/nrd4419
    CrossrefPubMedGoogle Scholar
  • 14 Holmes D. Therapy: FGF1 restores blood glucose levels and insulin sensitivity in diabetic mice. Nature reviews Endocrinology 2014; 10: 576 doi:10.1038/nrendo.2014.129
    PubMedGoogle Scholar
  • 15 Zhu JZ, Zhu HT, Dai YN. et al. Serum periostin is a potential biomarker for non-alcoholic fatty liver disease: A case-control study. Endocrine 2016; 51: 91-100 doi:10.1007/s12020-015-0735-2
    CrossrefPubMedGoogle Scholar
  • 16 Zhu JZ, Li CX, Dai YN. et al. Serum betatrophin level increased in subjects with nonalcoholic fatty liver disease. Int J Clin Exp Med 2016; 9: 6580-+
    PubMedGoogle Scholar
  • 17 Zhou BF. Cooperative Meta-Analysis Group of the Working Group on Obesity in C. Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults–study on optimal cut-off points of body mass index and waist circumference in Chinese adults. Biomedical and environmental sciences: BES 2002; 15: 83-96
    PubMedGoogle Scholar
  • 18 Mejhert N, Galitzky J, Pettersson AT. et al. Mapping of the fibroblast growth factors in human white adipose tissue. The Journal of clinical endocrinology and metabolism 2010; 95: 2451-2457 doi:10.1210/jc.2009-2049
    CrossrefPubMedGoogle Scholar
  • 19 Suh JM, Jonker JW, Ahmadian M. et al. Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer. Nature 2014; 513: 436-439 doi:10.1038/nature13540
    CrossrefPubMedGoogle Scholar
  • 20 Perry RJ, Lee S, Ma L. et al. FGF1 and FGF19 reverse diabetes by suppression of the hypothalamic-pituitary-adrenal axis. Nature communications 2015; 6: 6980 doi:10.1038/ncomms7980
    CrossrefPubMedGoogle Scholar
  • 21 Scarlett JM, Rojas JM, Matsen ME. et al. Central injection of fibroblast growth factor 1 induces sustained remission of diabetic hyperglycemia in rodents. Nature medicine 2016; 22: 800-806 doi:10.1038/nm.4101
    CrossrefPubMedGoogle Scholar
  • 22 European association for the study of the Liver. Electronic address eee, European association for the study of D, European association for the study of O. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Journal of hepatology 2016; 64: 1388-1402 doi:10.1016/j.jhep.2015.11.004
    PubMedGoogle Scholar
  • 23 Liu W, Struik D, Nies VJ. et al. Effective treatment of steatosis and steatohepatitis by fibroblast growth factor 1 in mouse models of nonalcoholic fatty liver disease. Proceedings of the National Academy of Sciences of the United States of America 2016; 113: 2288-2293 doi:10.1073/pnas.1525093113
    CrossrefPubMedGoogle Scholar
  • 24 Wang S, Yang Q, Yu S. et al. Fibroblast growth factor 1 levels are elevated in newly diagnosed type 2 diabetes compared to normal glucose tolerance controls. Endocrine journal 2016; 63: 359-365 doi:10.1507/endocrj.EJ15-0627
    CrossrefPubMedGoogle Scholar